Presented By Solon Alva Antibody Purification Group Lead, Senior Scientific Manager, Biocon Research Limited
Continuous manufacturing is an emerging technology in biopharmaceutical industry. The focus of this webinar is a case-study on the benefits of continuous Protein A capture on productivity, capacity utilization and buffer consumption. The potential challenges of adopting the technology such as its integration with cell culture and low pH incubation step has been discussed. There is promise of this technology as an effective platform, and potential of additional savings when considering new generation Protein A resins and in-line concentration technologies.
Followed by Yvan Ruland, PhD, Technology Director, Asia/Pacific operations, Novasep Asia